Skip to main content
Top

Cancer Chemotherapy and Pharmacology

Issue 2/2008

Content (19 Articles)

Original Article

Cell death in response to antimetabolites directed at thymidylate synthase

Karen W. Barbour, Franklin G. Berger

Original Article

Glutamine and alanyl-glutamine accelerate the recovery from 5-fluorouracil-induced experimental oral mucositis in hamster

R. F. C. Leitão, R. A. Ribeiro, A. M. S. Lira, L. R. Silva, E. A. L. Bellaguarda, F. D. B. Macedo, R. B. Sousa, G. A. C. Brito

Original Article

Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells

David H. Holman, Lorianne S. Turner, Ahmed El-Zawahry, Saeed Elojeimy, Xiang Liu, Jacek Bielawski, Zdzislaw M. Szulc, Kristi Norris, Youssef H. Zeidan, Yusuf A. Hannun, Alicja Bielawska, James S. Norris

Original Article

Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO

Jalid Sehouli, Dirk Stengel, Alexander Mustea, Oumar Camara, Elke Keil, Dirk Elling, Peter Ledwon, Bernd Christiansen, Peter Klare, Gerhard Gebauer, Marina Schwarz, Werner Lichtenegger

Original Article

Pharmacokinetics of the adrenocorticolytic compounds 3-methylsulphonyl-DDE and o,p′-DDD (mitotane) in Minipigs

Veronica Hermansson, Tatiana Cantillana, Lotta Hovander, Åke Bergman, Karl Ljungvall, Ulf Magnusson, Karolina Törneke, Ingvar Brandt

Original Article

A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer

Takeshi Kato, Hideyuki Mishima, Masakazu Ikenaga, Kouhei Murata, Hideyuki Ishida, Mutsumi Fukunaga, Hirofumi Ota, Shusei Tominaga, Tadashi Ohnishi, Masahiro Amano, Kimimasa Ikeda, Masataka Ikeda, Mitsugu Sekimoto, Junichi Sakamoto, Morito Monden

Original Article

Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer

Bassel F. El-Rayes, Mark M. Zalupski, Stephanie G. Manza, Barbara Rusin, Ann Marie Ferris, Ulka Vaishampayan, Lance K. Heilbrun, Raghu Venkatramanamoorthy, Anthony F. Shields, Philip A. Philip

Original Article

Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system

Mark N. Kirstein, Richard C. Brundage, Megan M. Moore, Brent W. Williams, Lisa A. Hillman, Jason W. Dagit, James E. Fisher, Paul H. Marker, Robert A. Kratzke, Douglas Yee

Original Article

Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy

Jong Gwang Kim, Baek-Yeol Ryoo, Yeon Hee Park, Bong-Seog Kim, Tae-You Kim, Young-Hyuck Im, Yoon-Koo Kang

Original Article

Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy

Hye Jin Choi, Byoung Chul Cho, Sang Joon Shin, Seong Ha Cheon, Jong Yul Jung, Joon Chang, Se Kyu Kim, Joo Hyuk Sohn, Joo Hang Kim

Original Article

A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer

Chong Kun Im, Hei-Cheul Jeung, Sun Young Rha, Nae Choon Yoo, Sung Hoon Noh, Jae Kyung Roh, Hyun Cheol Chung

Original Article

Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients

Takeharu Yamanaka, Shigemi Matsumoto, Satoshi Teramukai, Ryota Ishiwata, Yoji Nagai, Masanori Fukushima

Short Communication

Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda®) monotherapy

Gregor Fürstenberger, Peter Schmid, Ans Duquesne, Maria Ammann, Hans-Jörg Senn

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine